Published in J Empir Res Hum Res Ethics on December 01, 2007
Factors related to voluntary parental decision-making in pediatric oncology. Pediatrics (2012) 1.01
Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment. Int J Tuberc Lung Dis (2012) 0.86
The Development of a Communication Tool to Facilitate the Cancer Trial Recruitment Process and Increase Research Literacy among Underrepresented Populations. J Cancer Educ (2015) 0.75
Evaluation of the Informed Consent Process of a Multicenter Tuberculosis Treatment Trial. AJOB Empir Bioeth (2015) 0.75
Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study. PLoS One (2017) 0.75
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep (2010) 8.16
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med (2011) 6.14
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis (2008) 2.69
Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med (2008) 2.55
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
Using GIS technology to identify areas of tuberculosis transmission and incidence. Int J Health Geogr (2004) 2.37
Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis (2007) 2.33
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med (2006) 2.33
Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis (2007) 2.28
Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med (2011) 2.17
Risk-based human immunodeficiency virus (HIV) testing fails to detect the majority of HIV-infected persons in medical care Settings. Sex Transm Dis (2006) 2.07
Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS (2008) 2.02
Pulmonary impairment after tuberculosis. Chest (2007) 1.97
Latent TB infection treatment acceptance and completion in the United States and Canada. Chest (2009) 1.97
Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med (2004) 1.96
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (2009) 1.95
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
What is the outcome of targeted tuberculosis screening based on universal genotyping and location? Am J Respir Crit Care Med (2006) 1.64
Underuse of effective measures to prevent and manage pediatric tuberculosis in the United States. Arch Pediatr Adolesc Med (2008) 1.62
Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis (2010) 1.59
Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med (2005) 1.58
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis (2012) 1.53
Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest (2007) 1.45
Widespread emergence of methicillin resistance in community-acquired Staphylococcus aureus infections in Denver. South Med J (2005) 1.44
Avoidable antibiotic exposure for uncomplicated skin and soft tissue infections in the ambulatory care setting. Am J Med (2013) 1.44
Transmission of drug-resistant tuberculosis in Texas and Mexico. J Clin Microbiol (2002) 1.40
Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One (2011) 1.38
Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy (2002) 1.31
Skin-test screening and tuberculosis transmission among the homeless. Emerg Infect Dis (2002) 1.28
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother (2007) 1.26
NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen. J Immunol (2004) 1.23
Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr (2003) 1.21
Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial. AIDS (2010) 1.20
The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol (2002) 1.17
Personal and societal health quality lost to tuberculosis. PLoS One (2009) 1.12
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol (2010) 1.11
How much directly observed therapy is enough? Am J Respir Crit Care Med (2004) 1.10
Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr (2005) 1.07
Epidemiology of healthcare-associated bloodstream infection caused by USA300 strains of methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Infect Control Hosp Epidemiol (2009) 1.07
Does directly observed therapy (DOT) reduce drug resistant tuberculosis? BMC Public Health (2011) 1.05
ESAT-6 inhibits production of IFN-gamma by Mycobacterium tuberculosis-responsive human T cells. J Immunol (2009) 1.04
Multiple cytokines are released when blood from patients with tuberculosis is stimulated with Mycobacterium tuberculosis antigens. PLoS One (2011) 1.04
Antibiotic prescribing practices in a multicenter cohort of patients hospitalized for acute bacterial skin and skin structure infection. Infect Control Hosp Epidemiol (2014) 1.04
Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health (2010) 1.02
Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2013) 1.00
Tuberculosis in patients with HIV infection. Infect Dis Clin North Am (2002) 1.00
HIV transmission risk behavior and its relation to antiretroviral treatment adherence. Sex Transm Dis (2003) 0.99
Early clinical experience with networked system for promoting patient self-management. Am J Manag Care (2011) 0.99
The 'Antiretrovirals, Sexual Transmission Risk and Attitudes' (ASTRA) study. Design, methods and participant characteristics. PLoS One (2013) 0.96
Durability of adherence to antiretroviral therapy on initial and subsequent regimens. AIDS Patient Care STDS (2006) 0.96
CD40 ligand trimer enhances the response of CD8+ T cells to Mycobacterium tuberculosis. J Immunol (2003) 0.94
The societal cost of tuberculosis: Tarrant County, Texas, 2002. Ann Epidemiol (2010) 0.93
The association between symptoms and microbiologically defined response to tuberculosis treatment. Ann Am Thorac Soc (2013) 0.92
The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy (2008) 0.92
Serum cytokine concentrations do not parallel Mycobacterium tuberculosis-induced cytokine production in patients with tuberculosis. Clin Infect Dis (2002) 0.91
Using cost and health impacts to prioritize the targeted testing of tuberculosis in the United States. Ann Epidemiol (2005) 0.91
The hunt for the elusive surrogate marker of sterilizing activity in tuberculosis treatment. Am J Respir Crit Care Med (2003) 0.91
Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis. J Infect Public Health (2011) 0.91
Reduced expression of nuclear cyclic adenosine 5'-monophosphate response element-binding proteins and IFN-gamma promoter function in disease due to an intracellular pathogen. J Immunol (2002) 0.90
Initial linkage and subsequent retention in HIV care for a newly diagnosed HIV-infected cohort in Denver, Colorado. J Int Assoc Provid AIDS Care (2013) 0.90
Treatment of active tuberculosis: challenges and prospects. Clin Chest Med (2005) 0.89
Measuring health-related quality of life in tuberculosis: a systemic review--response. Health Qual Life Outcomes (2010) 0.88
Human CD8+ T cells recognize epitopes of the 28-kDa hemolysin and the 38-kDa antigen of Mycobacterium tuberculosis. J Leukoc Biol (2003) 0.87
Caveat emptor? Meta-analysis of studies comparing self-observed therapy and directly observed therapy for tuberculosis. Clin Infect Dis (2013) 0.86
Mycobacterium tuberculosis specific CD8(+) T cells rapidly decline with antituberculosis treatment. PLoS One (2013) 0.85
Allopatric tuberculosis host-pathogen relationships are associated with greater pulmonary impairment. Infect Genet Evol (2013) 0.81
What are the costs of suspected but not reported tuberculosis? Ann Epidemiol (2006) 0.80
Engagement-in-care during the first 5 years after HIV diagnosis: data from a cohort of newly HIV-diagnosed individuals in a large US city. AIDS Patient Care STDS (2014) 0.80
Clinical characteristics and antibiotic utilization in pediatric patients hospitalized with acute bacterial skin and skin structure infection. Pediatr Infect Dis J (2014) 0.79
Risk factors for drug-resistant Streptococcus pneumoniae and antibiotic prescribing practices in outpatient community-acquired pneumonia. Acad Emerg Med (2012) 0.79
Non-hispanic whites have higher risk for pulmonary impairment from pulmonary tuberculosis. BMC Public Health (2012) 0.79
Mortality hazard and survival after tuberculosis treatment. Am J Public Health (2015) 0.78
Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. Pharmacotherapy (2007) 0.78
Comparison of the microbiology and antibiotic treatment among diabetic and nondiabetic patients hospitalized for cellulitis or cutaneous abscess. J Hosp Med (2014) 0.78
Associate investigations: detection of tuberculosis infections in children resulting in discovery of undiagnosed tuberculosis in adults. J Am Osteopath Assoc (2002) 0.78
Assessing the impact of targeted tuberculosis interventions. Am J Respir Crit Care Med (2008) 0.75
Sorting out icebergs, mirages, and clinical tuberculosis during active case finding. Am J Respir Crit Care Med (2009) 0.75
Using economic analysis to improve tuberculosis control. Int J Tuberc Lung Dis (2009) 0.75
Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort. J Am Osteopath Assoc (2002) 0.75
Conventional and molecular epidemiology of macrolide resistance among new Mycobacterium avium complex isolates recovered from HIV-infected patients. Clin Infect Dis (2005) 0.75
Short-course regimens for latent tuberculosis: what is ready for prime time? Enferm Infecc Microbiol Clin (2007) 0.75